SEC Form 4 · accession 0000899243-18-021425
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tricia Borga Suvari
Officer — Chief Legal Officer
Period of report
Aug 1, 2018
Accepted (ET)
Aug 3, 2018 · 5:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 1, 2018 | M | 3,250 | — | A | 9,400 | D | |
| Common StockF2 | Aug 1, 2018 | F | 1,124 | $43.15 | D | 8,276 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Aug 1, 2018 | M | 3,250 | D | — | — | Common Stock | 3,250 | 22,750 | D |
Explanation of responses
- F1Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
- F2Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,250 shares of Common Stock underlying the Reporting Person's RSUs.
- F3The RSUs vest in eight equal semi-annual installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer.